View metadata, citation and similar papers at core.ac.uk
brought to you by CORE
provided by AIR Universita degli studi di Milano

1 **Flow cytometric characterization of S-phase fraction and ploidy in lymph node aspirates from**
2 **dogs with lymphoma**

3 Barbara Miniscalco[*], Alessia Poggi[*], Valeria Martini[†], Emanuela Morello[*], Majlind Sulce[*],
4 Maverick Melega[*], Antonio Borrelli[*], Alberto Tarducci[*], Fulvio Riondato[*]

5 [*] *Department of Veterinary Sciences, University of Turin, Largo Braccini 2, Grugliasco, Turin,*
6 *Italy.*

7 [†] *Department of Veterinary Medicine, University of Milan, via Celoria 10, Milan, Italy.*

8

9 *Corresponding author: Fulvio Riondato*

10 *Email: fulvio.riondato@unito.it*

11 *Phone number: +390116709068*

12

13 This research did not receive any specific grant from funding agencies in the public, commercial, or
14 not-for-profit sectors.

15

16 **Abstract**

17 Canine lymphoma is a multifaceted disease encompassing numerous entities with different
18 prognosis. Objective assessment of the proliferation rate is of great importance from both
19 pathological and clinical point of view. Different methods have been described in the literature to
20 assess it, including evaluation of Ki67 expression on fresh lymph node (LN) aspirates by flow
21 cytometry (FC). This test has a high accuracy in discriminating low- and high-grade lymphomas,
22 and provides prognostic information among high-grade B-cell lymphomas. DNA content analysis is
23 less expensive and suitable for preserved samples. We describe DNA-content analysis on LN
24 aspirates from 112 dogs with lymphoma. Based on our results, S-phase fraction (SPF) accurately
25 discriminates between low and high-grade lymphomas, being 3.15% the best discriminating cut-off.
26 SPF values strongly correlate with Ki67 expression assessed by FC. Survival analyses were
27 restricted to 33 dogs with high-grade B-cell lymphoma receiving a standardized multi-agent
28 chemotherapy, but no significant result for SPF was obtained. We also describe a subset of
29 aneuploid cases and their respective follow-up. We conclude that DNA content analysis may be
30 combined with morphological examination of LN aspirates to improve the objectivity in lymphoma
31 subtype classification in dogs. Further studies are needed to assess possible prognostic role of both
32 SPF and ploidy status within specific lymphoma subtypes in the canine population.

33

34 **Keywords**

35 Proliferation rate, DNA content, Ki67, aneuploidy

36

37 **Introduction**

38 The definition of neoplasia has evolved during the past decades, as new concepts were taken into
39 account, such as sustenance of the proliferative signalling, evasion of growth suppression,
40 resistance to cell death, replicative immortality and induction of angiogenesis (Hanahan and
41 Weinberg, 2000; Vincent, 1987; Willis, 1952). However, uncontrolled proliferation continues to be
42 considered a hallmark of cancer cells (Fouad and Aanei, 2017; Golias et al., 2004; Hanahan and
43 Weinberg, 2000, 2011; Kaufman et al., 2007). Indeed, dysregulation of the cell cycle is a major
44 contributor to the pathogenesis of neoplasms (Dictor et al., 1999; Wiman and Zhivotovsky, 2017).

45 The DNA content of the cells varies with progression in the cell cycle: cells in G0 and G1 phases
46 maintain two complete sets of chromosome (diploid cells, 2n); during the S-phase, the DNA
47 amount progressively increases until duplication; cells in G2 and M phases are tetraploid (4n).
48 Thus, cell distribution within the phases of the cell cycle can be revealed analysing the DNA
49 content of the cellular population. This is generally achieved via flow cytometry (FC), using
50 fluorescent DNA dyes (Darzynkiewicz et al., 2017; Ormerod et al., 1998; Wilkerson 2012) and
51 particularly assessing the fraction of cells in S-phase (SPF). As replicating DNA is more prone to
52 carcinogen attacks, S-phase is a crucial step of the cell cycle in the process of neoplastic
53 transformation and development (Kaufman et al., 2007).

54 In dogs, DNA content and ploidy have been described for transitional cell carcinomas of urinary
55 bladder, mast cell tumours, melanomas, mammary tumours, osteosarcomas and lymphomas (Ayl et
56 al., 1992; Bolon et al., 1990; Clemo et al., 1994; Fox et al., 1990; Hellmen et al., 1993; Teske et al.,
57 1993).

58 In particular, Teske and colleagues investigated the DNA content and ploidy status in canine
59 lymphoma, but failed to detect any correlation with lymphoma subtype or phenotype, and with
60 survival (Teske et al., 1993). Canine lymphoma is a heterogeneous disease and encompasses
61 numerous entities with different clinical presentation, behaviour and follow up (Aresu et al., 2015;

62 Valli et al 2013). The study by Teske and colleagues dates back to 1993 and was based on the
63 Working Formulation (WF) classification scheme. From then on, other classification schemes have
64 been introduced for canine lymphoma. Based on a recent review, the WF classification appears to
65 be of poor clinical and prognostic interest, differently from both the World Health Organization
66 (WHO) histopathological scheme and the updated Kiel cytological scheme (Sayag et al., 2018).
67 Still, morphological evaluation alone remains operator-dependent, and the inclusion of other
68 objective data can contribute to improve the intra- and inter-observer reproducibility (Teske and van
69 Heerde, 1996).

70 The combined use of cytology, immunophenotype and FC assessment of Ki67 expression has been
71 recently proposed as a reliable tool for the classification of canine lymphomas (Poggi et al., 2015).
72 Ki67 FC quantification has also a prognostic value in dogs with high-grade B-cell lymphomas
73 (Poggi et al., 2017). Unfortunately, this technique has been applied only on fresh samples (within
74 24 hours from sampling) in the dog (Poggi et al., 2015). In addition, changes >20% in Ki67
75 expression are reported in human blood stored for 72-96 hours before analysis, even if collected in
76 tubes containing a cell preservative commonly used for FC analysis (Sun et al., 2016). On the
77 contrary, preserved or archive material is suitable for DNA content analysis (Ormerod et al., 1998).
78 In addition, this technique is less expensive, requiring only fluorescent DNA dyes, whereas
79 monoclonal antibodies and permeabilizing solutions are needed to assess Ki67 expression via FC
80 (Kim and Sederstrom, 2015).

81 Aim of the present study was to assess the diagnostic and prognostic role of DNA content analysis
82 in canine lymphomas. In particular, we describe: 1) the S-phase fraction (SPF) in different
83 lymphoma subtypes; 2) the correlation of SPF with other proliferation rate markers (Ki67); 3) the
84 prevalence of aneuploidy and the follow up of aneuploid cases; and 4) the possible prognostic role
85 of SPF among dogs with high-grade B-cell lymphoma undergoing a standardized treatment
86 regimen.

87

Materials and methods

Case selection and classification

The FC database of the Veterinary Teaching Hospital of the University of Turin was retrospectively investigated from January 2011 to September 2014. All consecutive cases fulfilling the following inclusion criteria were extrapolated: 1) a final diagnosis of nodal lymphoma based on clinical presentation, complete blood count, cytological and FC examination of an enlarged peripheral lymph node (LN), 2) availability of a LN cytological sample for review, and 3) availability of FC immunophenotype and DNA content analysis on LN. Dogs treated with corticosteroids or chemotherapy agents prior to FC analysis were excluded as well as samples of poor quality for DNA content analysis: Background Aggregates and Debris (BAD) >20% and/or G0/G1 peak Coefficient of Variation (CV) >8% (Ormerod et al., 1998).

All dogs were privately owned and sampled for diagnostic purposes with a written informed consent of the owners. Thus, a specific formal approval of the Institution Committee for Animal Care of the University of Turin was not required.

Cytological samples were reviewed by a single operator and cases were classified according to the updated Kiel classification scheme (Fournel-Fleury et al., 1997). LN aspirates collected into tubes containing RPMI-1640 or saline solution were processed for FC immunophenotyping within 24 hours from sampling as previously described (Gelain et al., 2008). Different combinations of the following monoclonal antibodies were used for this aim: CD45 (clone YKIX716.13), CD3 (clone CA17.2A12), CD5 (clone YKIX322.3), CD4 (clone YKIX302.9), CD8 (clone YCATE55.9), CD21 (clone CA2.1D6), CD79b (clone AT107-2), CD34 (clone 1H6). All antibodies were provided by Serotec (Oxford, UK) except CD34 (BD Becton Dickinson; San Josè, CA, USA). Ki67 expression was determined as previously described (Poggi et al., 2015). All samples were acquired with a BD

111 Accuri C6 (BD Becton Dickinson) and analysed with the specific software CFlow Plus (BD Becton
112 Dickinson).

113 For high-grade B-cell lymphoma and aneuploid tumours cases, the referring veterinarians were
114 contacted to retrieve signalment data (including breed, sex and age at diagnosis), as well as clinical
115 stage and substage according to the WHO staging system (Owen, 1980), and follow up data.

116 *DNA content analysis*

117 LN aspirates were fixed in 70% ethanol and stored at -20°C for a minimum of 2 hours, until
118 analysis for DNA content. Immediately prior to processing, all samples were washed twice in PBS
119 1x and the supernatant was finally discarded. 500µl of a staining solution containing propidium
120 iodide (50 µg/ml) and Ribonuclease (RNase, 0.2mg/ml) were added to the cell pellet ($1x10^6$
121 cells/tube), incubated for 15 minutes, and then acquired with the BD Accuri C6 flow cytometer.

122 Nucleated cells from peripheral blood of a healthy dog, obtained by RBC lysis with a solution
123 containing 8% ammonium chloride, fixed in 70% ethanol and stored at -20°C were processed along
124 with each neoplastic LN sample, to serve as a normal diploid control.

125 Analyses were performed with a dedicated software (Multicycle for Windows, in FCS Express).
126 Data were represented by a histogram with the fluorescence intensity on X-axis, and the number of
127 cells on Y-axis. The SPF was calculated as the area under the curve between G0/G1 and G2/M
128 peak.

129 Cases were considered aneuploid if two G0/G1 peaks were identified. When a single peak was
130 present or the diploid peak was not clearly recognizable, an aliquot of the control tube was added.
131 The DNA index (DI) was calculated as the ratio between the mean channel number of the G0/G1
132 extra-peak and the mean channel number of the G0/G1 diploid peak.

133 *Statistical analysis*

134 All statistical analyses were performed with a specific software (SPSS v21.0, SPSS Inc, Chicago, 135 USA) and significance was set at $p \leq 0.05$ for all tests.

136 Many cytological subtypes were poorly represented or absent in our case series. Thus, for statistical 137 purposes, cases were re-classified based on phenotype and cytological malignancy grade in: high-138 grade B-cell, high-grade T-cell, low-grade B-cell and low-grade T-cell subtypes.

139 A Shapiro-Wilk test was performed to assess whether SPF data were normally distributed within 140 groups. A Levene's test was performed to test the homoscedasticity assumption. Thereafter, 141 possible SPF variations among lymphoma subtypes were assessed with a Brown-Forsythe ANOVA 142 test. Post-hoc analyses were performed with a Dunnett test.

143 A Receiving Operator Curve (ROC) was drawn to select the SPF cut-off best discriminating 144 between low- and high-grade lymphomas, based on the best compromise between sensitivity and 145 specificity.

146 The Pearson's correlation coefficient between SPF and Ki67 expression was calculated. The 147 equation of the regression line was used to identify the SPF values corresponding to 20% and 40% 148 Ki67 expression, respectively, as these values were proved to be of prognostic impact in dogs with 149 high-grade B cell lymphoma (Poggi et al., 2017). These SPF cut-offs were then used for survival 150 analyses.

151 Survival analyses were restricted to dogs with high-grade B-cell lymphoma treated with a 25-weeks 152 Winsconsin-Madison chemotherapy protocol (UW-25) (Garrett et al., 2002), in order to reduce the 153 bias linked to inclusion of different lymphoma subtypes and treatment regimens.

154 Follow up data were also recorded for aneuploid cases, although survival analyses were not 155 attempted because of the low number of cases and the wide spectrum of lymphoma subtypes and 156 treatment regimens adopted.

157 According to the official guidelines (Vail et al., 2010), complete response (CR) was defined as
158 disappearance of all evidence of disease in target lesions, disease-free survival (DFS) as time from
159 documentation of CR and relapse, and lymphoma-specific survival (LSS) as time from initiation of
160 treatment and death for lymphoma. Dogs lost to follow up, still in CR at data analysis closure, or
161 dead for lymphoma-unrelated causes before lymphoma relapse were censored for DFS analyses.
162 Dogs lost to follow up, still alive at data analysis closure, or dead for lymphoma-unrelated causes
163 were censored for LSS analysis.

164 Univariate Cox's proportional hazard regression analysis was performed, to assess possible
165 influence on DFS and LSS of the following variables: breed (pure or mixed), sex (male or female),
166 age (< or ≥8 years), stage (I to V), substage (a or b), Ki67 expression (≤20%, between 20% and
167 40%, >40%), SPF (≤5.90%, between 5.90% and 11.72%, >11.72%), obtainment of CR (yes or not).
168 Variables with P-value ≤0.30 were then included in a backward elimination multivariate analysis. In
169 addition, Kaplan Meier curves were drawn and compared with log-rank test to assess possible
170 variations in median DFS and LSS according to the aforementioned variables.

171 **Results**

172 Overall, DNA content analysis was performed in 124 cases. Among them, 12 (9.7%) were of poor
173 quality (BAD >20% and/or G0/G1 peak CV >8%). Thus, 112 cases were finally included in the
174 study.

175 Concerning lymphoma subtype, 41 (36.6%) cases were centroblastic polymorphic B-cell, 16
176 (14.3%) centroblastic monomorphic B-cell, 10 (8.9%) small clear T-cell, 9 (8.0%) immunoblastic
177 B-cell, 9 (8.0%) pleomorphic mixed small and large T-cell, 6 (5.4%) macronucleolated medium-
178 sized B-cell, 6 (5.4%) pleomorphic large T-cell, 4 (3.6%) lymphoblastic B-cell, 4 (3.6%)
179 lymphoblastic T-cell, 3 (2.7%) pleomorphic small T-cell, and 1 (0.9%) each of the following:
180 plasmacytoid B-cell, plasmacytoid T-cell, prolymphocytic B-cell and prolymphocytic T-cell. Thus,

181 71 (63.4%) dogs had a high-grade B-cell lymphoma, 20 (17.9%) had a high-grade T-cell
182 lymphoma, 14 (12.5%) a low-grade T-cell lymphoma, and 7 (6.2) a low-grade B-cell lymphoma.

183 *S-phase fraction*

184 Overall mean SPF was 9.36±7.81% (median 8.50%; min-max 0.2-46.4%). In particular, high-grade
185 B-cell lymphomas had a mean SPF of 11.35±8.11% (median 9.30%; min-max 1.3-46.4%), high-
186 grade T-cell lymphomas a mean SPF of 10.95±4.60% (median 10.70%; min-max 3.4-21.5%), low-
187 grade T-cell lymphomas a mean SPF of 1.08±0.94% (median 0.85%; min-max 0.2-3.1%) and low-
188 grade B-cell lymphomas a mean SPF of 1.30±0.77% (median 1.30%; min-max 0.6-2.8%). SPF
189 values for specific cytological subtypes are listed in table 1.

190 SPF variation among lymphoma subgroups was statistically significant ($p<0.001$). In particular,
191 SPF was higher in high-grade B-cell than in low-grade B- and T-cell lymphomas and higher in
192 high-grade T-cell than in low-grade B- and T-cell lymphomas ($p<0.001$ for all comparisons).
193 Differences between high-grade B- and T-cell lymphomas and between low-grade B- and T-cell
194 lymphomas were not significant ($p>0.05$) (Fig.1).

195 ROC curve identified a high accuracy of SPF in discriminating between low- and high-grade
196 lymphomas (area under the curve AUC=0.996), being 3.15% the best cut-off (sensitivity 97.8%,
197 specificity 100.0%) to identify high-grade lymphomas.

198 *Correlation between SPF and Ki67*

199 Ki67 expression was assessed in 100 cases, with a mean overall value of 31.66±18.69% (median
200 30.00%; min-max 1.00-71.00%). A strong correlation between Ki67 expression and SPF was
201 detected ($p<0.001$, $r=0.753$). The equation was: SPF=0.075+0.291*Ki67. Thus, the SPF cut-offs
202 corresponding to 20% and 40% Ki67 expression were 5.90% and 11.72%, respectively. These cut-
203 offs were then used in the survival analyses.

204 *Ploidy*

Among the 112 cases included, 105 (93.8%) were diploid and 7 (6.2%) aneuploid. These included 3 (42.9%) high-grade B-cell lymphomas (2 immunoblastic and 1 centroblastic monomorphic), 3 (42.9%) high-grade T-cell lymphomas (2 pleomorphic mixed small and large and 1 lymphoblastic) and 1 (14.3%) low-grade T-cell lymphoma (pleomorphic small cells).

Mean DI of aneuploid cases was 1.20±0.07 (median 1.18; min-max 1.14-1.36). Five (71.4%) cases had DI<1.20 and were subclassified as near-diploid (Bauer et al 1993). A lymphoblastic T-cell lymphoma had a DI=1.21, and a centroblastic monomorphic B-cell lymphoma had a DI=1.36.

Breed was not reported in one case; the other dogs represented 6 different pure breeds. Three (42.9%) were females (1 spayed) and 4 (57.1%) males (1 neutered). Mean age at diagnosis was 10.8±2.3 years (median 11 years; min-max 7-14 years) but was not reported in one case.

Follow up data were available for the 5 near-diploid cases. One dog with high-grade B-cell lymphoma was treated with corticosteroid alone and was still alive after 58 days from the diagnosis; the other one entered the UW-25 chemotherapy protocol but died for lymphoma-unrelated causes after 45 days from the diagnosis. One dog with high-grade T-cell lymphoma was treated with single-agent chemotherapy and died for lymphoma on day 20; the other one entered the UW-25 chemotherapy protocol, had a DFS of 56 days and died for lymphoma on day 70. The dog with low-grade T-cell lymphoma received chlorambucile and prednisone, did not achieve CR and died for lymphoma on day 111.

Survival analyses

Follow up data were available for 51 dogs with high-grade B-cell lymphoma. Among them, 8 (15.7%) received prednisone alone, 6 (11.8%) no treatment, and 4 (7.8%) single-agent chemotherapy. Thus, survival analyses were restricted to 33 dogs that were treated with the UW-25 chemotherapy protocol.

228 Breed was known for 32 cases, including 21 (65.6%) pure-breed dogs of 17 different breeds and 11
229 (34.4%) mixed-breed. Sex was known for 32 cases, with 16 (50%) intact males and 16 (50%)
230 females (7 spayed). Among 29 dogs whose age was known, 13 (44.8%) were <8 years old and 16
231 (55.2%) were ≥8 years old. Twenty-nine dogs underwent full staging: 3 (10.3%) were classified as
232 stage IV disease and 26 (89.7%) as stage V. Eight (24.2%) dogs were in substage a and 25 (75.8%)
233 in substage b. Ki67 expression had been tested in 29 dogs: it was ≤20% in 5 (17.2%) dogs, between
234 20% and 40% in 16 (55.2%), and >40% in 8 (27.6%). SPF was ≤5.90% in 6 (18.2%) dogs out of 33,
235 between 5.90% and 11.72% in 19 (57.6%) dogs and >11.72% in 8 (24.2%) dogs. All dogs but one
236 were diploid: the aneuploid case had a DI of 1.18. Nineteen (59.4%) dogs achieved CR and 13
237 (40.6%) did not; this information was not available for 1 dog.

238 None of the 19 dogs that achieved CR was censored for DFS analysis. Overall median DFS was
239 235 days (range 14-747 days). Among the investigated variables, significant results were obtained
240 only for sex and Ki67 expression. In particular, median DFS was 349 days (range 159-747 days) for
241 female dogs and 102 days (range 14-508 days) for male dogs: significant results were obtained with
242 univariate and multivariate Cox's analysis (p=0.020 and p=0.022, respectively) as well as with log-
243 rank test (p=0.014). Median DFS was 159 days (range 159-200 days) for dogs with low Ki67
244 expression, 329 days (range 14-747 days) for dogs with intermediate Ki67 expression, and 75 days
245 (range 70-349 days) for dogs with high Ki67 expression significant results were obtained with
246 multivariate Cox's analysis (p=0.039) and with log-rank test (p=0.042); p-value for univariate
247 analysis was 0.063.

248 Ten (30.3%) dogs were censored for LSS analysis: 7 were still alive at data analysis closure with a
249 median follow-up of 528 days (range 28-872 days), whereas 3 died for lymphoma-unrelated causes
250 after 34, 45 and 210 days, respectively. Overall median LSS was 365 days (range 15-1086 days).
251 Among the investigated variables, significant results were obtained only by the achievement of CR
252 (p<0.001 for univariate Cox's analysis and log-rank test, and p=0.001 for multivariate analysis):

253 median LSS was 531 days (range 34-1086 days) for dogs that achieved CR and 45 days (range 15-
254 320 days) for dogs that did not. A difference in the median LSS was also noted among the three
255 Ki67 expression groups, although it did not reach statistical significance (p=0.099 for univariate
256 Cox's analysis and p=0.081 for log-rank test): median LSS was 240 days (range 34-365 days) for
257 dogs with low Ki67 expression, 728 days (range 28-1086 days) for dogs with intermediate Ki67
258 expression, and 150 days (range 15-872 days) for dogs with high Ki67 expression.

259 The datasets generated during and/or analysed during the current study are available from the
260 corresponding author on reasonable request

261 **Discussion**

262 DNA content analysis has been used in veterinary medicine to characterize the proliferative activity
263 of different neoplasms (Ayl et al., 1992; Bolon et al., 1990; Clemo et al., 1994; Fox et al., 1990;
264 Hellmen et al., 1993; Teske et al., 1993). In the present study, we describe the variation in SPF
265 among different lymphoma subtypes in dogs, and its diagnostic and prognostic implications. We
266 also describe a subset of aneuploid cases.

267 Identification of the malignancy grade is a crucial step in the diagnostic workup for dogs with
268 lymphoma because of its prognostic impact: high-grade lymphomas have a more aggressive clinical
269 behaviour than low-grade indolent lymphomas (Aresu et al., 2015; Ponce et al., 2004; Valli et al.,
270 2013). Indeed, assessment of the mitotic index is required by all morphological classification
271 schemes (either cytological or histopathological) (Fournel-Fleury et al., 1997; Greenle et al., 1990;
272 Teske et al., 1994). Morphological assessment is somewhat operator-dependent, and a slight level
273 of intra- and inter-observer disagreement may occur, even among the most experienced and
274 specialized pathologists (Valli et al., 2011). Thus, tools that more objectively estimate the
275 proliferation rate in histopathological sections of canine lymphomas have been introduced decades
276 ago, such as AgNOR count and Ki67 expression (Kiupel et al., 1998, 1999; Phillips et al., 2000).
277 Unfortunately, many veterinary oncologists do not include histopathological examination in their

diagnostic workup for canine lymphoma (Regan et al., 2013). Thus, strategies to quantify proliferation rate have been adapted to lymph node aspirates: AgNOR count can be performed with silver stain on cytological smears (Bauer et al., 2007), and Ki67 expression can be quantified either by immunostaining of cytological smears (Bauer et al., 2007) or by FC (Poggi et al., 2015).

Until now, DNA content in canine lymphoma has been analysed in one study only, on frozen tissue samples (Teske et al., 1993). In the present study, we used LN aspirates suspended in a liquid medium. This makes the examination more feasible for routine clinical practice, as surgical approach is not required. The opportunity of analysing different parameters on thousands of cells simultaneously, in face of a minimally invasive sampling procedure, is one of the major advantages of FC, and partially explains its wide spread in veterinary oncology (Burkhard and Bienzle, 2015; Comazzi and Gelain, 2011). FC has been used also to assess Ki67 expression in canine lymphomas, thus allowing a rapid and objective evaluation of the proliferative activity in a large number of cells (Poggi et al., 2015). Unfortunately, storage of the samples for few days can affect the results of this analysis (Sun et al., 2016). The technique presented in the present study fills this gap, as it combines the pros of FC (minimal invasiveness, rapidity, number of cells analysed) with the possible use of stored material from LN aspirates. Still, the analysis of Ki67 expression should be preferred whenever possible, as a relevant percentage of samples have to be excluded from DNA content analysis due to poor sample quality: we had to discard about 10% of the samples due to BAD>20% or CV>8%.

Based on our results, SPF accurately discriminates between high- and low-grade lymphomas in dogs. This is in contrast with the results obtained by Teske and colleagues (1993), who failed to detect any association between SPF and lymphoma malignancy. The difference in the samples used between the two studies (frozen tissues vs fresh ~~nodal~~LN aspirates) may partially explain this discrepancy, as well as the different classification schemes applied. In particular, the WF scheme includes three grades while only the low and high grade are described in the ~~Kiupel~~updated Kiel

scheme. Most of the cases in the study by Teske and colleagues were allocated exactly in the intermediate grade, which is not considered~~ not provided for~~ in the Kiel classification used in our study. Furthermore, Teske and colleagues did not stratify cases according to the neoplastic cells phenotype when analysing SPF data.

~~Furthermore, Teske and colleagues determined the B- vs T-cell lineage but they did not considered it for the classification. Cell lineage was detected only in a part of the tumors and a very different antibody panel was used.~~

Formattato: Evidenziato

Formattato: Evidenziato

In line with Teske and colleagues (1993), we found no prognostic significance for SPF. Different reasons may account for this lack of significant results in the two studies. Teske and colleagues included in the survival analysis many different lymphoma subtypes, irrespective of the phenotype and the malignancy grade. In order to avoid this bias, we restricted our analysis to high-grade B-cell lymphoma cases that underwent a standardized chemotherapy protocol. Unfortunately, only 33 dogs corresponded to these inclusion criteria, and about one third of them was censored for LSS analysis. Therefore, our results may be affected by a low statistical power and caution should be used when considering them. This may explain the lack of significant results for LSS among Ki67 expression groups, as the median values are in line with what previously reported by our research group (Poggi et al., 2017). This is also true for the significant results obtained for sex, which may be over-estimated: female dogs have a lower risk to develop lymphoma (Villamil et al., 2009) but to date a prognostic impact of male versus female sex has never been reported in dogs with lymphoma. Further studies are warranted, including a larger standardized case series.

SPF was strongly correlated with Ki67 expression in our cases series. ~~but if b~~Both parameters allow a reliable discrimination between high- and low- grade lymphomas, but survival analyses gave significant results only for the latter. The difference in the information provided by the two techniques may account for this: all proliferating cells stain positive for Ki67, whereas only the subset of cells in the S-phase of the cell cycle are counted with DNA content analysis. In addition,

the SPF cut-offs we selected may be unsuitable to discriminate different prognostic groups, and other values may work better.

Even though both analyses (Ki67 and DNA content) can be run in a routine panel for canine lymphoma diagnosis, ~~in our experience~~ Ki67 determination is currently the first choice because of the limitations of SPF and ploidy as prognostic markers. Furthermore, the protocol for Ki67 determination is common to all intracytoplasmic labelling (it can easily be run beside the immunophenotyping analysis) and does not use hazardous reagents such as propidium iodide. SPF remains an excellent second option in the case the analysis must be delayed.

Contrasting results have been obtained also in human medicine about the clinical usefulness of DNA content analysis for non-Hodgkin's lymphomas: some studies claim for a prognostic value of SPF and/or ploidy status (Joensuu et al., 1991; Lackowska et al., 1999; Pinto et al., 2003; Rehn et al., 1990) whereas other authors downsize this hypothesis (Winter et al., 1996). A more recent study performed on a large case series of human non-Hodgkin's lymphomas revealed a prognostic impact for SPF (but not ploidy status) only within specific subtypes (namely, B-cell small lymphocytic lymphoma, diffuse large B-cell lymphoma and anaplastic large cell lymphoma) (Lackowska et al., 2012): the different inclusion criteria used may therefore account for the different results obtained in human medicine. Such a detailed study is still lacking for canine lymphoma.

The prevalence of aneuploidy in our case series (6.2%) was lower compared to the one previously reported in dogs with lymphoma (21.3%) (Teske et al., 1993). This is likely due to the different criteria used to define aneuploidy. Indeed, we only selected cases were two distinct G0/G1 peaks were identifiable, whereas Teske and colleagues also included cases with marked asymmetry and high CV in the G0/G1 peak. This difference particularly affects the possibility to correctly classify near-diploid cases: samples with DI only slightly >1 may have gone unnoticed in cases with high

352 G0/G1 peak CV in our case series, whereas aneuploid cases with higher DI are more easily
353 detected, irrespective of the CV.

354 Teske and colleagues (1993) found no prognostic relevance for ploidy status. We did not attempt
355 such an analysis because of the low number of aneuploid cases. Interestingly, however, a complete
356 follow up was available for 3 aneuploid T-cell lymphoma cases: the 2 high-grade cases died for
357 lymphoma after 20 and 70 days, respectively, and the only low-grade case died for lymphoma after
358 111 days. This is in line with what already reported for dogs with high-grade T-cell lymphomas
359 (Aresu et al., 2015), whereas dogs with low-grade T-cell lymphoma commonly have a longer
360 survival (Martini et al 2016; Valli et al., 2013). Further studies including a large cohort of aneuploid
361 cases with a complete follow up are needed to assess whether ploidy status may affect survival
362 within specific lymphoma subtypes.

363 Future investigation should also be aimed at clarify potential diagnostic role of aneuploidy in dogs
364 with lymphoma. Based on a recent study, indeed, numerical chromosomal aberrations found in the
365 tumour of dogs with lymphoma are often present also in the peripheral blood. Therefore, the authors
366 hypothesize the use of peripheral blood as a matrix for cytogenetic analysis to monitor the status of
367 the disease during treatment (Devitt et al., 2009). Gross numerical chromosomal aberrations may
368 lead to aneuploidy (Sansregret and Swanton, 2017). If aneuploidy is detected in peripheral blood
369 from dogs with lymphoma, it may serve as a case-specific tumour fingerprint to assess the minimal
370 residual disease after treatment. To the authors' knowledge, however, DNA content in the
371 peripheral blood from dogs with lymphoma has never been investigated, and these considerations
372 remain purely speculative.

373 ~~Even though both analyses can be run in a routine panel for canine lymphoma diagnosis, in our~~
374 ~~experience Ki67 determination is currently the first choice because of the limitations of SPF and~~
375 ~~ploidy as prognostic markers. Furthermore, the protocol for Ki67 determination is common to all~~
376 ~~intracytoplasmic labelling (it can easily be run beside the immunophenotyping analysis) and does~~

~~not use hazardous reagents such as propidium iodide. SPF remains an excellent second option in the case the analysis must be delayed~~

The retrospective nature of the present study represents its major limitation, as well as the small number of aneuploid cases included: these two factors prevented us from performing large-scale survival analyses and perhaps from identifying a prognostic role for the parameters investigated. In addition, only lymphoma samples were included in the present study, and the power of SPF to discriminate between neoplastic and non-neoplastic LNs is still to be elucidated.

In conclusion, DNA content analysis can be of aid to assess the malignancy grade on LN aspirates from dogs with lymphoma. These data can be combined to the morphological examination to improve the objectivity in the subtype definition. Identification of the prognostic role of both SPF and ploidy status requires further studies on a large number of cases.

Acknowledgements

Authors wish to thank all of the practitioners who provided samples for the present study.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sector.

Conflict of interest

The authors declare no conflict of interest.

References

Aresu L, Martini V, Rossi F, Vignoli M, Sampaolo M et al. (2015) Canine indolent and aggressive lymphoma: clinical spectrum with histologic correlation. *Veterinary and Comparative Oncology,* 13, 348-362.

Ayl RD, Couto CG, Hammer AS, Weisbrode S, Ericson JG et al. (1992) Correlation of DNA ploidy to tumor histologic grade, clinical variables, and survival in dogs with mast cell tumours. *Veterinary Pathology*, 29, 386-390.

Bauer KD, Bagwell B, Giaretti W, Melamed M, Zarbo RJ et al. (1993) Consensus review of the clinical utility of DNA flow cytometry in colorectal cancer. *Cytometry*, 14, 486-491.

Bauer NB, Zervos D, Moritz A (2007) Argyrophilic nucleolar organizing regions and ki67 equally reflect proliferation in fine needle aspirates of normal, hyperplastic, inflamed, and neoplastic canine lymph nodes (n=101). *Journal of Veterinary Internal Medicine*, 21, 928-935.

Bolon B, Calderwood Mays MB, Hall BJ (1990) Characteristics of canine melanomas and comparison with histology and DNA ploidy to their biologic behaviour. *Veterinary Pathology*, 27, 96-102.

Burkhard MJ, Bienzle D (2015) Making sense of lymphoma diagnostics in small animal patients. *Clinics in Laboratory Medicine*, 35, 591-607.

Clemo FA, DeNicola DB, Carlton WW, Morrison WB, Walker E (1994) Flow cytometric DNA ploidy analysis in canine transitional cell carcinoma of urinary bladders. *Veterinary Pathology*, 31, 207-215.

Comazzi S, Gelain ME (2011) Use of flow cytometric immunophenotyping to refine the cytological diagnosis of canine lymphoma. *Veterinary Journal*, 188, 149-155.

416 Darzynkiewicz Z, Huang X, Zhao H (2017) Analysis of cellular DNA content by flow cytometry.
417 *Current Protocols in Cytometry*, 82, 7.5.1-7.5.20

418 Devitt JJ, Maranon DJ, Ehrhart EJ, Bachand AM, Lana SE et al (2009) Correlations between
419 numerical chromosomal aberrations in the tumor and peripheral blood in canine lymphoma.
420 *Cytogenetic and Genome Research*, 124, 12-18.

421 Dictor M, Ehinger M, Mertens F, Akervall J, Wennerberg J (1999) Abnormal cell cycle regulation
422 in malignancy. *American Journal of Clinical Pathology*, 112, S40-52.

423 Fouad YA, Aanei C (2017) Revisiting the hallmarks of cancer. *American Journal of Cancer*
424 *Research*, 7, 1016-1036.

425 Fournel-Fleury C, Magnol JP, Bricaire P, Marchal T, Chabanne L et al (1997) Cytohistological and
426 immunological classification of canine malignant lymphomas: comparison with human non-
427 Hodgkin's lymphomas. *Journal of Comparative* Pathology, 117, 35-59.

428 Fox MH, Armstrong LW, Withrow SJ, Powers BE, LaRue SM (1990) Comparison of DNA
429 aneuploidy of primary and metastatic spontaneous canine osteosarcomas. *Cancer Research*, 50,
430 6176-6178.

431 Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM (2002) Evaluation of a 6 month
432 chemotherapy protocol with no maintenance therapy for dogs with lymphoma. *Journal of*
433 *Veterinary Internal Medicine*, 16, 704-709.

434 Gelain ME, Mazzilli M, Riondato F, Marconato L, Comazzi S (2008) Aberrant phenotypes and
435 quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry.
436 *Veterinary Immunology and Immunopathology*, 12, 179-188.

437 Golias CH, Charalabopoulos A, Charalabopoulos K (2004) Cell proliferation and cell cycle control:
438 a mini review. *International Journal of Clinical Practice*, 58, 1134-1141.

439 Greenlee PG, Filippa DA, Quimby FW, Patnail AK, Calvano SE et al. (1990). Lymphomas in dogs.
440 A morphologic, immunologic, and clinical study. *Cancer*, 66, 480-490.

441 Hanahan D, Weinberg RA (2000). The hallmarks of cancer. *Cell*, 100, 57-70.

442 Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. *Cell*, 144, 646-674.

443 Hellmen E, Bergstrom R, Holmberg L, Spangberg IB, Hansson K et al. (1993) Prognostic factors in
444 canine mammary tumours: a multivariate study of 202 consecutive cases. *Veterinary Pathology*, 30,
445 20-27.

446 Joensuu H, Klemi PJ, Söderström KO (1991). Comparison of S-phase fraction, working
447 formulation, and Kiel classification in non-Hodgkin's lymphoma. *Cancer*, 68, 1564-1571.

448 Kaufman DG, Cordeiro-Stone M, Brylawski BP, Cohen SM, Chastain PD (2007) Early S phase
449 DNA replication: a search for targets of carcinogenesis. *Advances in Enzyme Regulation*, 47, 127-
450 138.

451 Kim KH, Sederstrom JM (2015) Assaying cell cycle status using flow cytometry. *Current Protocols*
452 *in Molecular Biology*, 111, 28.6.1-11.

453 Kiupel M, Bostock D, Bergmann V (1998) The prognostic significance of AgNOR counts and
454 PCNA-positive cell counts in canine malignant lymphomas. *Journal of Comparative Pathology*,
455 119, 407-418.

456 Kiupel M, Teske E, Bostock D (1999) Prognostic factors for treated canine malignant lymphoma.
457 *Veterinary Pathology*, 36, 292-300.

458 Lackowska B, Gruchala A, Niezabitowski A, Radkowski A, Skołyszewski J et al. (1999) Prognostic
459 and predictive evaluation of DNA content, S-phase fraction and immunophenotyping in non-
460 Hodgkin's lymphomas in adults: a prospective study. *Polish Journal of Pathology*, 50, 23-29.

461 Lackowska B, Gruchala A, Jaszcz-Gruchala A, Rolski J, Zemełka T et al. (2012) Diagnostic,
462 predictive and prognostic verification of DNA flow cytometric measurements performed at
463 diagnosis for non-Hodgkin's lymphoma adult patients. *Polish Journal of Pathology*, 1, 18-24.

464 Martini V, Marconato L, Poggi A, Riondato F, Aresu L et al. (2016) Canine small clear cell/T-zone
465 lymphoma: clinical presentation and outcome in a retrospective case series. *Veterinary and*
466 *Comparative Oncology*, 14 suppl 1, 117-126.

467 Ormerod MG, Tribukait B, Giaretti W (1998) Consensus report of the task force on standardization
468 of DNA flow cytometry in clinical pathology. *Analytical Cellular Pathology*, 17, 103-110.

469 Owen L (1980) TNM Classification of tumours in domestic animals. World Health Organization,
470 Geneva, Switzerland, 46-47.

471 Phillips BS, Kass PH, Naydan DK, Winthrop MD, Griffey SM et al. (2000) Apoptotic and
472 proliferation indexes in canine lymphoma. *Journal of Veterinary Diagnostic Investigations,* 12,
473 111-117.

474 Pinto AE, Cabeçadas J, Nóbrega SD, Mendonça E (2003) Flow cytometric S-phase fraction as a
475 complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
476 *Diagnostic Cytopathology*, 29, 194-199.

477 Poggi A, Miniscalco B, Morello E, Comazzi S, Gelain ME et al. (2015) Flow cytometric evaluation
478 of ki67 for the determination of malignancy grade in canine lymphoma. *Veterinary and*
479 *Comparative Oncology*, 13, 475-480.

480 Poggi A, Miniscalco B, Morello E, Gattino F, Delaude A et al. (2017) Prognostic significance of
481 ki67 evaluated by flow cytometry in dogs with large B-cell lymphoma. *Veterinary and Comparative*
482 *Oncology*, 15, 431-440.

483 Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V et al. (2004) Prognostic significance of
484 morphological subtypes in canine malignant lymphomas during chemotherapy. *Veterinary Journal*,
485 167, 158-166.

486 Regan RC, Kaplan MS, Bailey DB (2013). Diagnostic evaluation and treatment reccomendations
487 for dogs with substage-a high grade multicentric lymphoma: results of a survey of veterinarians.
488 *Veterinary and Comparative Oncology*, 11, 287-295.

489 Rehn S, Glimelius B, Strang P, Sundström C, Tribukait B (1990). Prognostic significance of flow
490 cytometry studies in B-cell non-Hodgkin lymphoma. *Hematological Oncology*, 8, 1-12.

491 Sansregret L, Swanton C (2017) The role of aneuploidy in cancer evolution. *Cold Spring Harbor*
492 *Perspectives in Medicine*, 7(1), a028373.

493 Sayag D, Fournel-Fleury C, Ponce F (2018) Prognostic significance of morphotypes in canine
494 lymphomas: a systematic review of literature. *Veterinary and Comparative Oncology*, 16(1), 12-19.

495 Sokolowska J, Micun J, Malicka E, Lechowski R (2012) Proliferation activity in canine
496 lymphomas. *Polish Journal of Veterinary Sciences*, 15, 727-734.

497 Sun Y, Yang K, Bridal T, Ehrhardt AG (2016) Robust Ki67 detection in human blood by flow
498 cytometry for clinical studies. *Bioanalysis*, 8, 2399-2413.

499 Teske E, Rutteman GR, Kuipers-Dijshoorn NJ, van Dierendonck JH, van Heerde P et al. (1993)
500 DNA ploidy and cell kinetic characteristics in canine non-Hodgkin's lymphoma. *Experimental*
501 *Hematology*, 21, 579-584.

502 Teske E, Wisman P, Moore PF, van Heerde P (1994) Histologic classification and
503 immunophenotyping of canine non-Hodgkin's lymphomas: unexpected high frequency of T-cell
504 lymphomas with B cell morphology. *Experimental Hematology*, 22, 1179-1187.

505 Teske E, van Heerde P (1996) Diagnostic value and reproducibility of fine-needle aspiration
506 cytology in canine malignant lymphoma. *The Veterinary Quarterly*, 18, 112-115.

507 Valli VE, San Myint M, Barthel A, Bienzle D, Caswell J et al. (2011) Classification of canine
508 malignant lymphomas according to the World Health Organization criteria. *Veterinary Pathology*,
509 48, 198-211.

510 Valli VE, Kass PH, San Myint M, Scott F (2013) Canine lymphomas: association of classification
511 type, disease stage, tumor subtype, mitotic rate and treatment with survival. *Veterinary Pathology*,
512 50, 738-748.

513 Villamil JA, Henry CJ, Hahn AW, Bryan JN, Tyler JW et al. (2009) Hormonal and sex impact on
514 the epidemiology of canine lymphoma. *Journal of Cancer Epidemiology*, 2009, 591753.

515 Vincent MD (1987) The definition of a neoplasm. *Medical Hypotheses*, 24, 151-160.

516 Willis RA (1952) The Spread of Tumors in the Human Body. Butterworth & Co, London

517 Wilkerson MJ (2012) Principles and applications of flow cytometry and cell sorting in companion
518 animal medicine. *The Veterinary Clinics of North America. Small Animal Practice,* 42, 53-71.

519 Wiman KG, Zhivotovsky B (2017) Understanding cell cycle and cell death regulation provides
520 novel weapons against human diseases. *Journal of Internal Medicine*, 281, 483-495.

521 Winter JN, Andersen J, Variakojis D, Gordon LI, Fisher RI et al. (1996) Prognostic implications of
522 ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas. *Blood*, 88,
523 3919-3925.

524

525 **Fig.1** Distribution of S-phase fraction values within the four subtypes of lymphoma considered in

526 the study (high grade B-cell, low grade B-cell, high grade T-cell, and low grade T-cell)